Iron is an essential element of various metabolic processes in humans including DNA synthesis, electron transport, and oxygen transport. Unlike other minerals, iron levels in the human body are controlled only by absorption. The mechanism of iron excretion is an unregulated process arrived at through loss in sweat, menstruation, shedding of hair and skin cells, and through rapid turnover and excretion of enterocytes. In the human body, iron exists mainly in erythrocytes as the heme compound hemoglobin (approximately 2 g of iron in men and 1.5 g in women), to a lesser extent in storage compounds (ferritin and hemosiderin) and in muscle cells as myoglobin. Iron also is found bound to proteins (hemoprotein) and in non-heme enzymes involved in oxidation-reduction reactions and the transfer of electrons (cytochromes and catalase).
In addition, approximately 2.2% of total body iron is found in the so-called labile pool, a poorly defined and reactive pool of iron that forms reactive oxygen species via the Fenton Reaction which forms complexes with a drug class known as chelators. Iron chelators treat iron overload, a condition often caused by transfusion therapies that are used to treat thalassemias and other anemias.
There are two types of absorbable dietary iron: heme and non-heme iron.
Despite its relative abundance in the environment and the relatively low daily iron requirements (10mg ingested/1 mg absorbed) of humans, iron is often a growth-limiting nutrient in the human diet. Low intake of iron accounts for most anemia in developed countries and is responsible for nearly half of the anemias in non-industrialized nations. One reason for the lack of adequate iron absorption is that upon exposure to oxygen, iron forms highly insoluble oxides which are unavailable for absorption in the human gastrointestinal tract. Human enterocytes contain apical membrane-bound enzymes whose activity can be regulated and which function to reduce insoluble ferric (Fe3+) to absorbable ferrous (Fe2+) ions.
Although iron deficiency is a relatively common problem, it is not the only extreme of the iron-balance spectrum that must be avoided. Iron overload can be particularly damaging to the heart, liver, and endocrine organs. Excess ferrous iron forms free hydroxyl radicals via the Fenton reaction that cause damage to tissues through oxidative reactions with lipids, proteins, and nucleic acids. Thus, dietary iron absorption and factors affecting bioavailability in the body are tightly regulated where possible.
The absorption of most dietary iron occurs in the duodenum and proximal jejunum and depends heavily on the physical state of the iron atom. At physiological pH, iron exists in the oxidized, ferric (Fe3+) state. To be absorbed, iron must be in the ferrous (Fe2+) state or bound by a protein such as heme. The low pH of gastric acid in the proximal duodenum allows a ferric reductase enzyme, duodenal cytochrome B (Dcytb), on the brush border of the enterocytes to convert the insoluble ferric (Fe3+) to absorbable ferrous (Fe2+) ions. The gastric acid production plays a key role in plasma iron homeostasis. When proton-pump inhibiting drugs such as omeprazole are used, iron absorption is greatly reduced. Once ferric iron is reduced to ferrous iron in the intestinal lumen, a protein on the apical membrane of enterocytes called divalent metal cation transporter 1 (DMT1) transports iron across the apical membrane and into the cell. Levels of DMT1 and Dcytb are upregulated in the hypoxic environment of the intestinal mucosa by hypoxia-inducible factor-2 (HIF-2α).
The duodenal pH-dependent process of iron absorption is inhibited or enhanced by certain dietary compounds.
Once inside the enterocyte, iron can be stored as ferritin or transported through the basolateral membrane and into circulation bound to ferroportin. (Ferritin that is not bound to iron is called apoferritin, which has an intrinsic catalytic activity that oxidizes ferrous iron into ferric iron so that it can be bound and stored as ferritin.)
Ferritin is a hollow, spherical protein consisting of 24 subunits that potentiate the storage and regulation of iron levels within the body. Iron is stored in the Fe3+ state on the inside of the ferritin sphere through incorporation into a solid crystalline mineral called ferrihydrite [FeO(OH)]8[FeO(H2PO4)].
Monomers of the ferritin molecule have ferroxidase activity (Fe3+ ↔ Fe2+) which allows the mobilization of Fe2+ ions out of the ferrihydrite mineral lattice structure, enabling its subsequent efflux out of the enterocyte via ferroportin, and into circulation across the basolateral membrane of the enterocyte. The transmembrane protein ferroportin is the only efflux route of cellular iron and is regulated almost exclusively by hepcidin levels. High levels of iron, inflammatory cytokines, and oxygen lead to increased levels of the peptide hormone hepcidin. Hepcidin binds ferroportin, resulting in its internalization and degradation and effectively shunting cellular iron into ferritin stores and preventing its absorption into the blood. Thereby, hepcidin also potentiates the excretion of iron through sloughing of enterocytes (and their ferritin stores) into the feces and out of the body.
If hepcidin levels are low and ferroportin is not downregulated, ferrous (Fe2+) iron can be released from the enterocyte, where it is oxidized once again into ferric (Fe3+) iron for binding to transferrin, its carrier protein which is present in the plasma. Two copper-containing enzymes, ceruloplasmin in the plasma and hephaestin on the basolateral membrane of the enterocyte catalyze the oxidation of and subsequent binding of ferrous iron to transferrin in the plasma. The principal role of transferrin is to chelate iron so that it can be rendered soluble, prevent the formation of reactive oxygen species, and facilitate its transport into cells.
Enterocyte DMT1 and Dcytb levels are upregulated in cases of iron deficiency anemia, and mutations in DMT1 have been shown to give rise to microcytic anemias and liver iron overload.
Conditions that degrade the mucosa of the duodenum will decrease absorption of iron and include:
Anemia of chronic disease is a normochromic, normocytic anemia which shows characteristically elevated ferritin stores but lower total body iron. Inflammatory states increase cytokine release (IL-6) which stimulates hepcidin expression in the liver. Hepcidin causes decreased iron absorption through ferroportin degradation and decreases the release of iron from macrophages. The iron that accumulates in cells in anemia of chronic disease is stored as ferritin.
Iron-deficiency anemia is a hypochromic, microcytic anemia caused by hemorrhage (most commonly through trauma or gastrointestinal lesions), decreased dietary iron, or decreased iron absorption. Menstruating women of reproductive age require twice the amount of iron as similarly-aged men. Pregnancy and breastfeeding also significantly increase the iron requirements of women, helping to make iron deficiency the most common dietary deficiency in the world.
|||Rodgers GM,Gilreath JA, The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. Acta haematologica. 2019 Apr 10; [PubMed PMID: 30970366]|
|||Gómez-Ramírez S,Bisbe E,Shander A,Spahn DR,Muñoz M, Management of Perioperative Iron Deficiency Anemia. Acta haematologica. 2019 Apr 10; [PubMed PMID: 30970362]|
|||Gafter-Gvili A,Schechter A,Rozen-Zvi B, Iron Deficiency Anemia in Chronic Kidney Disease. Acta haematologica. 2019 Apr 10; [PubMed PMID: 30970355]|
|||DeLoughery TG, Safety of Oral and Intravenous Iron. Acta haematologica. 2019 Apr 10; [PubMed PMID: 30970354]|
|||Chuncharunee S,Teawtrakul N,Siritanaratkul N,Chueamuangphan N, Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand. PloS one. 2019; [PubMed PMID: 30893381]|
|||Shokrgozar N,Golafshan HA, Molecular perspective of iron uptake, related diseases, and treatments. Blood research. 2019 Mar; [PubMed PMID: 30956958]|
|||Demosthenous C,Vlachaki E,Apostolou C,Eleftheriou P,Kotsiafti A,Vetsiou E,Mandala E,Perifanis V,Sarafidis P, Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology (Amsterdam, Netherlands). 2019 Dec; [PubMed PMID: 30947625]|
|||Zusman O,Itzhaki Ben Zadok O,Gafter-Gvili A, Management of Iron Deficiency in Heart Failure. Acta haematologica. 2019 Apr 10; [PubMed PMID: 30970349]|
|||Wan D,Wu Q,Ni H,Liu G,Ruan Z,Yin Y, Treatments for iron deficiency (ID): Prospective organic iron fortification. Current pharmaceutical design. 2019 Mar 18; [PubMed PMID: 30892157]|